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Introduction
• The third most commonly
diagnosed cancer in men and
women combined in the
U.S..
• The second leading cause of
cancer death in men and
women combined in the U.S.
• 70% Of adults screened
• Colonoscopy at age 50 now
lowered to age 45
• 30% of CRC diagnoses are
under age 55.
• The 5-year relative survival
rate for stage 1 and stage II
colon cancer is 90%; the 5year survival rate for patients
diagnosed at stage III is 71%
and stage IV is 14%.
• PDX:Tumor tissue that has
been taken from a patient and
implanted into mice for
research purposes. Cancer
drugs and other types of
treatment may be tested on
xenografts to see how well
they work before they are
given to the patient.

Methods

Fig. 1: Example of a PDX Model. Human
tumor collected and surgically implanted into
immunocomprised mouse and than removed.
Removed tumor cut up and put into more mice.

The methods of Protocol 20191016
1. Gets blood and tissues samples
with the predictive biomarkers
activity ad immune effects for
the treatments.
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Clinical Trial
• .The best does of LY3214996
with CETUXIAMB alone or
with ABEMACIABLBE for
patients with colorectal cancer
that cannot be removed by
surgery or has spread to other
parts of the body.
• LY3214996/AMEMACICILB
may stop the growth of tumor
cells by blocking some enzymes
needed for cell growth.
• Cextuxiamb is a monoclonal
antibody that may infer with the
ability of tumor cells to grow
and spread

mouse to test the combination of
mouse with LY3214996 WITH
CETUXIAMB alone or with
ABEMACICLIB in two different
mouse sets to test for biomarker
response and mechanism of
resistance in LY3214996 with
CETUXIAMB and LY3214996
,CETUXIAMB, and
ABEMACICLIB.

2.Surgical implant them into

Conclusions

immune comprised mouse
Subcutaneous in matched
patients it cetuximab refractory
metastatic colorectal cancer.
Remove the tumor and expand
the tumor into more immune
comprised mouse. Do some
molecular profiling.

.Clinical Trial: Patients

3.You can do pcr or western
blots to test for DNA or rna in
the drugs tested.

Objectives
• To analyze how PDX are
turned into clinical trial for
treating colorectal cancer.
From tumors extracted from
patient and implanted into
immunocompromised mouse
and treated with drugs to see if
it viable for human testing.
Afterwards clinical trial are
started to test the drugs in
colorectal cancer patients

4.Expand the tumor into more
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Fig. 3:. A 2D Model of a cells metastasis.
bActin

Figure 4: An example of Inhibition of
MAPK pathway induces dMMR

• The PDX model is an
effective way in treating
patient with colorectal
cancer as it mimic or
somewhat predict the
toxicity and its
effectiveness.
• Protocol 2019-1016 I still
ongoing therefore there is
currently no results but its
primary outcome measure is
overall response and best
response

• 2 arms both start with 2 arms with
dose escalation
• 1st arm: Erk ½ inhibitor
LY3214996 orally and cetuxiamb
over 1-2 hrs. Repeat every 28
cycle continuation depends on
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